Skip to main content

Table 2 List of MDM2-p53 inhibitors in ongoing clinical trials

From: Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Drug Disease Combination with   Phase Status Trial nr Sponzor Start date
Idasanutlin (RG7388) Breast cancer Atezolizumab Anti-PD-L1 I/II Active, not recruiting NCT03566485 Vanderbilt-Ingram Cancer Center 2018
  Acute myelogenous leukemia (AML), acute lymphocytic leukemia, neuroblastoma, solid tumors Cyclophosphamide
  I/II Recruiting NCT04029688 Hoffmann-La Roche 2020
  Relapsed multiple myeloma Ixazomib
  I/II Active, not recruiting NCT02633059 Mayo Clinic 2021
AMG-232 (KRT-232) Acute myelogenous leukemia, relapsed and refractory AML Decitabine DNA damage I Recruiting NCT03041688 National Cancer Institute 2017
  Soft tissue sarcoma Radiation therapy   Ib Recruiting NCT03217266 National Cancer Institute 2017
  Polycythemia vera Ruxolitinib TK inhibitor II Active, not recruiting NCT03669965 Kartos Therapeutics, Inc 2018
  Relapsed multiple myeloma Carfilzomib
Proteosome inhibitor
I Recruiting NCT03031730 National Cancer Institute 2017
  Brain cancer Radiation therapy   I Recruiting NCT03107780 National Cancer Institute 2018
  Acute myelogenous leukemia Cytarabine
Idarubicin HCl
DNA damage
DNA damage
Ib Recruiting NCT04190550 National Cancer Institute 2020
APG-115 (AA-115) Metastatic melanomas, advanced solid tumors Pembrolizumab Anti-PD-1 Ib/II Recruiting NCT03611868 Ascentage Pharma Group, Inc. 2018
  Salivary gland carcinoma Carboplatin DNA damage I/II Recruiting NCT03781986 Ascentage Pharma Group, Inc. 2019
  Acute myelogenous leukemia (AML), acute lymphocytic leukemia, neuroblastoma Azacitidine
DNA damage
DNA damage
Ib Recruiting NCT04275518 Ascentage Pharma Group, Inc. 2020
  Acute myelogenous leukemia 5-azacitidine DNA damage Ib/II Recruiting NCT04358393 Ascentage Pharma Group, Inc. 2020
  Liposarcoma, advanced solid tumors Toripalimab Anti-PD-1 Ib/II Not yet recruiting NCT04785196 Ascentage Pharma Group, Inc. 2021
  T-prolymphocytic leukemia APG-2575   IIa Not yet recruiting NCT04496349 Ascentage Pharma Group, Inc. 2021
BI907828 Solid tumors    Ia/Ib Recruiting NCT03449381 Boehringer Ingelheim 2018
  Solid tumors Ezanbenlimab
Ia/Ib Recruiting NCT03964233 Boehringer Ingelheim 2019
Uveal melanoma LXS196 PKC inhibitor I Recruiting NCT02601378 Novartis Pharmaceuticals 2016
  Advanced/metastatic colorectal cancer Trametinib MEK inhibitor I Recruiting NCT03714958 Centre Leon Berard 2018
  Myelofibrosis Ruxolitinib TK inhibitor I/II Recruiting NCT04097821 Novartis Pharmaceuticals 2019
  Range of cancers Spartalizumab Anti-PD-1 I Recruiting NCT02890069 Novartis Pharmaceuticals 2016
  Malignant solid tumors Ribociclib CDK inhibitor II Recruiting NCT04116541 Centre Leon Berard 2020
  Acute myelogenous leukemia Midostaurin TK inhibitor I Recruiting NCT04496999 University Hospital Inselspital, Berne 2020
  Acute myelogenous leukemia, myelodysplastic syndromes MBG453
BCL-2 inhibitor
Ib Recruiting NCT03940352 Novartis Pharmaceuticals 2021
Acute myelogenous leukemia, relapsed and refractory AML Cytarabine
DNA damage
BCL-2 inhibitor
I/II Recruiting NCT03634228 M.D. Anderson Cancer Center 2018
ALRN-6924 Pediatric cancer Cytarabine DNA damage I Recruiting NCT03654716 Dana-Farber Cancer Institute 2018
  Small cell lung cancer Topotecan   Ib/II Recruiting NCT04022876 Aileron Therapeutics 2019
  Breast cancer, malignant solid neoplasm Paclitaxel   Ib Recruiting NCT03725436 M.D. Anderson Cancer Center 2019
  1. TK tyrosine kinase, PKC protein kinase C